|
|
|
| Construction and validation of a senescence-associated secretory phenotype associated lncRNAs model to predict prognosis in patients with hepatocellular carcinoma |
| ZHOU Dingjie GE Wei CAO Dedong |
Oncology Center, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China
|
|
|
|
Abstract Objective To construct a senescence-associated secretory phenotype(SASP) related risk model that can independently predict the prognosis of hepatocellular carcinoma (HCC), and to improve the clinical efficacy of HCC. Methods Sequencing and clinical data of HCC were obtained from the cancer genome atlas(TCGA) database, and lncRNA were isolated. SASP related genes with correlation coefficient ＞ seven were searched and screened from the GeneCard website, and genes related to differentially expressed SASP associated lncRNAs were screened using the R language “limma” package. Cox regression analysis and lasso were used to construct the lncRNAs prediction model related to SASP. HCC patients were divided into high-risk group and low-risk group according to the median risk score of the samples. Kaplan-Meier curve was used for survival analysis. Single sample gene set enrichment analysis (ssGSEA) was used to investigate the association between risk scores and immune status in samples. Results A total of 374 tumor samples and 50 normal tissue samples were obtained from the TCGA database. Six lncRNAs associated with SASP were selected form a prognostic model, and the risk scores of each sample were calculated. Survival analysis showed that the prognosis of patients in the low-risk group was better than that in the high-risk group. Area under one-year survival receiver operating characteristic curve of risk model was 0.812. Univariate and multivariate regression analysis showed that patient risk score was an independent risk factor for HCC prognosis (OR ＞ 1, P ＜ 0.05). ssGSEA results showed higher expression levels of immune checkpoint specific targets and associated pathways in the high-risk group. Conclusion In this study, the SASP-related lncRNAs risk model is successfully constructed, and the risk model can independently predict the prognosis of HCC patients.
|
|
|
|
|
|
[1] Yang JD，Hainaut P，Gores GJ，et al. A global view of hepato- cellular carcinoma：trends，risk，prevention and manage- ment [J]. Na Rev Gastroenterol Hepatol，2019，16（10）：589- 604.
[2] Allemani C，Matsuda T，Di Carlo V，et al. Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）：analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J]. Lancet，2018，391（10125）：1023-1075.
[3] Birch J，Gil J. Senescence and the SASP：many therapeutic avenues [J]. Genes Dev，2020，34（23-24）：1565-1576.
[4] Chambers CR，Ritchie S，Pereira BA，et al. Overcoming the senescence-associated secretory phenotype （SASP）：a complex mechanism of resistance in the treatment of cancer [J]. Mol Oncol，2021，15（12）：3242-3255.
[5] Wang X，Wang J，Tsui YM，et al. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2 [J]. Nat Commun，2021，12（1）：1518-1534.
[6] Liu H，Zhao H，Sun Y. Tumor microenvironment and cellular senescence：Understanding therapeutic resistance and harnessing strategies [J]. Semin Cancer Biol，2022，86（Pt 3）：769-781.
[7] Tam C，Wong JH，Tsui SKW，et al. LncRNAs with miRNAs in regulation of gastric，liver，and colorectal cancers：updates in recent years [J]. Appl Microbiol Biotechnol，2019，103（12）：4649-4677.
[8] Ahmad S，Abbas M，Ullah MF，et al. Long non-coding RNAs regulated NF-κB signaling in cancer metastasis：Micromanaging by not so small non-coding RNAs [J]. Semin Cancer Biol，2022，85：155-163.
[9] Wang M，Yu F，Chen X，et al. The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma [J]. Mol Ther Nucleic Acids，2020，21：13-27.
[10] Chang K，Creighton CJ，Davis C，et al. The Cancer Genome Atlas Pan-Cancer analysis project [J]. Nature Genetics，2013， 45（10）：1113-1120.
[11] Martin FJ，Amode MR，Aneja A，et al. Ensembl 2023 [J]. Nucleic Acids Res，2023，51（D1）：D933-D941.
[12] Safran M，Rosen N，Twik M，et al. The GeneCards Suite [M]//Abugessaisa I，Kasukawa T. Practical Guide to Life Science Databases. Singapore; Springer Nature Singapore，2021：27-56.
[13] Ritchie ME，Phipson B，Wu D，et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic Acids Res，2015，43（7）：47-58.
[14] Engebretsen S，Bohlin J. Statistical predictions with glmnet [J]. Clin Epigenetics，2019，11（1）：123-131.
[15] H?覿nzelmann S，Castelo R，Guinney J. GSVA：gene set variation analysis for microarray and RNA-Seq data [J]. BMC Bioinformatics，2013，14（1）：7-14.
[16] Chidambaranathan-Reghupaty S，Fisher PB，Sarkar D. Hepatocellular carcinoma （HCC）：Epidemiology，etiology and molecular classification [J]. Adv Cancer Res，2021，149：1332-1355.
[17] Vogel A，Meyer T，Sapisochin G，et al. Hepatocellular carcinoma [J]. Lancet，2022，400（10360）：1345-1362.
[18] Liu P，Tang Q，Chen M，et al. Hepatocellular Senescence：Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma [J]. Fronti Oncol，2020， 10：5899-5908.
[19] Ma Y，Li S，Ye S，et al. Hexavalent chromium triggers hepatocytes premature senescence via the GATA4/NF-κB signaling pathway mediated by the DNA damage response [J]. Ecotoxicol Environ Saf，2022，239（11）：36-45.
[20] Huang W，Hickson LJ，Eirin A，et al. Cellular senescence：the good，the bad and the unknown [J]. Nat Rev Nephrol，2022， 18（10）：611-627.
[21] Liu H，Zhao H，Sun Y. Tumor microenvironment and cellular senescence：Understanding therapeutic resistance and harnessing strategies [J]. Semin Cancer Biol，2022， 86：769- 781.
[22] Fang Y，Yang Y，Li N，et al. Emerging role of long noncoding RNAs in recurrent hepatocellular carcinoma [J]. World J Clin Cases，2021，9（32）：9699-9710.
[23] Oh C，Koh D，Jeon HB，et al. The Role of Extracellular Vesicles in Senescence [J]. Mol Cells，2022，45（9）：603-609.
[24] Wirtz TH，Saal A，Bergmann I，et al. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma [J]. Br J Pharmacol，2021，178（22）：4452-4467.
[25] Zhou D，Wang Y，Hu H，et al. lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613：a primary study using contrast ultrasound [J]. World J Surg Oncol，2022，20（1）：203-221.
[26] Lu J，Guo J，Liu J，et al. Long Non-coding RNA MALAT1：A Key Player in Liver Diseases [J]. Front Med （Lausanne），2021，8（6）：734-743. |
|
|
|
